Company / Revenue
Esperion Therapeutics, Inc. Revenue History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Revenue
$403.1M
FY2025
5-year range
$75.5M / $403.1M
FY2021-FY2025
Trend
+21.3%
vs FY2024
Sector context
#71 of 155
Health Care
What the data says
At $403M, Esperion Therapeutics, Inc.'s revenue ranks #71 of 155 in the Health Care sector. Revenue has increased for 3 consecutive years, from $75M in FY2022 to $403M in FY2025.
Based on SEC 10-K filings.
$403M in FY2025 with a 5-year CAGR of +12.1%.
Improved from $116M to $403M over the past 2 years.
Health Care sector context is included.
Revenue over time
Growth rates
- 3-Year CAGR
- +74.8%
- 5-Year CAGR
- +12.1%
- 10-Year CAGR
- -
Sector benchmark
#71 of 155 in Health CareTop 46% of 155This company $403.1M Sector average $4.5B
▼
-91.0% below sector average
Key checks
Key Insights
- Esperion Therapeutics, Inc.'s revenue has grown for 3 consecutive years.
- 5-year CAGR of +12.1%, indicating consistent growth.
- In FY2025, revenue increased 21.3% year-over-year.
- Ranks #71 out of 155 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score -1.60 (distress zone, below 1.8 threshold)
- Negative profit margin: -15.6%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $403.1M | +21.3% |
| FY2024 | $332.3M | +185.7% |
| FY2023 | $116.3M | +54.1% |
| FY2022 | $75.5M | -3.8% |
| FY2021 | $78.4M | -65.5% |
| FY2020 | $227.5M | +53.4% |
| FY2019 | $148.4M | - |
| FY2018 | $0 | - |
| FY2017 | - | - |
| FY2016 | - | - |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026